If the body is driven more by information than by chemistry, why not treat disease with information? This question led Matthew Scholz to biology, and, ultimately, to Immusoft Corporation, a Seattle company he founded in 2009. Immusoft technology programs B cells, part of the body’s immune system, to treat disease. … By tweaking the code that tells the cells what to produce, Immusoft can make them into tiny treatment factories that continue to operate inside the body. In March, Immusoft acquired Minneapolis-based Discovery Genomics, which has a process that makes it far easier and cheaper to program the cells.